Frontage Laboratories, Inc.

Frontage Laboratories, Inc., a minority-owned, Asian-Pacific American-owned for-profit contract research organization (CRO) based in Exton, Pennsylvania, provides preclinical drug development and biomedical research services to the National Institutes of Health as a prime contractor on purchase orders and as a subcontractor to prime research organizations. The vendor competes predominantly full-and-open rather than under set-asides, with the exception of a single 2026 Total Small Business set-aside award; the parent entity carries manufacturer-of-goods and contracts-and-grants designations, and operates a subsidiary, Frontage Clinical Services, Inc.

Frontage's capability portfolio centers on contract research services: in vivo pharmacokinetic and metabolism studies, compound synthesis, blood stability testing, hepatocyte metabolism analysis, preclinical toxicology studies, and animal-model-based efficacy and fertility assessments supporting drug development pipelines for antiviral, antiretroviral, contraceptive, and investigational therapeutic compounds. Representative work includes a $222,500 Total Small Business purchase order awarded July 2026 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (ultimate completion July 2027), a $155,100 full-and-open purchase order from NIDDK in July 2023 for Compound 21 and in vivo pharmacokinetics studies, and an $88,000 full-and-open order from NIDDK in August 2022 for pharmacokinetic and metabolism research on small-molecule antivirals. Additional work under the National Center for Advancing Translational Sciences includes a mitragynine pharmacokinetics study in cynomolgus monkeys completed in 2022 for $11,000.

Customer concentration is highly concentrated with NIH institutes. NIDDK dominates the portfolio at 13 awards (65% of total) and $1.2 million combined potential value (92% of the portfolio). The National Institute of Child Health and Human Development, National Center for Advancing Translational Sciences, National Heart Lung and Blood Institute, and National Institute of Allergy and Infectious Diseases collectively account for the remaining 7 awards and $157,000 in combined potential value. The top-customers-by-award-count and top-customers-by-potential-value rankings are coterminous — NIDDK drives both volume and dollars. Across the portfolio, testing laboratories and services account for 10 awards and research and development in physical, engineering, and life sciences account for 5 awards.

Recent activity has been intermittent: 3 awards in 2022, 2 in 2023, 2 in 2024, 2 in 2025, and 1 awarded in 2026. Only one award (combined potential value $223,000) reaches ultimate completion within the next twenty-four months, creating minimal recompete exposure in that window. The vendor places work on several parent vehicles including the NIAID Professional, Scientific and Technical Support Services vehicle, the GSA Multiple Award Schedule, and the Professional Services Schedule, though task-order volume per vehicle is low (one task order per vehicle across the portfolio).

In its subcontractor role, Frontage performs preclinical services under Mitchell Group, Inc. on a December 2025 sub for protocol development supporting NIAID priority vaccine toxicology studies, under Camris International, LLC on an October 2025 sub for general safety toxicology studies, and under Medical Science & Computing, LLC and Westwind Computer Products, Inc. on 2024 subs supporting the National Heart, Lung, and Blood Institute CATALYZE Program preclinical services component. The vendor's prime-to-sub split runs 80% prime and 20% sub, indicating it builds its own delivery capability but supplements with subcontractor teaming on specific research components. Service Contract Inventory reporting is minimal — only one SCI record in FY2024 as a named subcontractor, representing 2.3 FTEs and below the commercial service-rate visibility threshold. The combined potential value of $1.3 million across all awards is substantially exceeded by combined obligated dollars of $3 million, reflecting the vendor's history of fixed-price purchase orders that complete on or ahead of ceiling values.